Addex Pharma, S.A.
Records under this name other than the patents Addex Pharma, S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,101,637 | Alkynyl derivatives as modulators of metatropic glutamate receptors Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,779,129 | Novel Triazinedione Derivatives as Gabab Receptor Modulators Lapsed on the fee record Ended Jul 15, 2026 · High confidence | Lapsed on the fee record | Ended Jul 15, 2026 | High confidence |
| US 9,765,091 | NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Formerly held Lapsed on the fee record Ended Sep 19, 2025 · High confidence | Lapsed on the fee record | Ended Sep 19, 2025 | High confidence |
| US 8,674,106 | Alkynyl derivatives as modulators of metabotropic glutamate receptors Term ended Ended no later than Jun 17, 2025 · From the USPTO record | Term ended | Ended no later than Jun 17, 2025 | From the USPTO record |
| US 8,883,826 | Alkynyl derivatives as modulators of metabotropic glutamate receptors Term ended Term ended Jun 17, 2025 · From the USPTO record | Term ended | Term ended Jun 17, 2025 | From the USPTO record |
| US 8,399,493 | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors Formerly held Lapsed on the fee record Ended Mar 19, 2025 · From the USPTO record | Lapsed on the fee record | Ended Mar 19, 2025 | From the USPTO record |
| US 9,266,834 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors Lapsed on the fee record Ended Feb 23, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 23, 2024 | From the USPTO record |
| US 9,226,930 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders Lapsed on the fee record Ended Jan 5, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 5, 2024 | From the USPTO record |
| US 9,085,577 | 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors Lapsed on the fee record Ended Jul 21, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jul 21, 2023 | From the USPTO record |
| US 8,946,205 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors Lapsed on the fee record Ended Feb 3, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 3, 2023 | From the USPTO record |